Menu
Search
|

Menu

Close
X

CTI Biopharma Corp CTIC.OQ (NASDAQ Stock Exchange Capital Market)

3.98 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 3.98
Open --
Volume --
3m Avg Volume 121,053
Today’s High --
Today’s Low --
52 Week High 5.36
52 Week Low 2.46
Shares Outstanding (mil) 42.98
Market Capitalization (mil) 140.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
10
FY17
25
FY16
57
FY15
16
EPS (USD)
FY18
-0.082
FY17
-1.285
FY16
-1.709
FY15
-6.618
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
3.86
5.73
Price to Book (MRQ)
vs sector
3.24
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
34.58
16.72
LT Debt to Equity (MRQ)
vs sector
15.71
12.39
Return on Investment (TTM)
vs sector
-85.83
14.61
Return on Equity (TTM)
vs sector
-127.14
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3101 Western Ave Ste 800
SEATTLE   WA   98121-3017

Phone: +1206.2827100

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

SPONSORED STORIES